Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A
Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including imidazole, glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, … Read more
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246) - Total Liabilities
Latest total liabilities as of June 2025: CN¥1.58 Billion CNY
Based on the latest financial reports, Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (301246) has total liabilities worth CN¥1.58 Billion CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A - Total Liabilities Trend (2021–2024)
This chart illustrates how Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Xinpeng Industry Co Ltd
SHE:002328
|
China | CN¥1.82 Billion |
|
Gs Retail
KO:007070
|
Korea | ₩4.51 Trillion |
|
Shenzhen Liande Automatic Equipment Co Ltd
SHE:300545
|
China | CN¥806.34 Million |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥1.16 Billion |
|
Sipef S.A.
LSE:0JSU
|
UK | €204.86 Million |
|
Nagacorp Ltd
PINK:NGCRF
|
USA | $279.42 Million |
|
Columbia Financial Inc
NASDAQ:CLBK
|
USA | $9.86 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A (2021–2024)
The table below shows the annual total liabilities of Hubei Hongyuan Pharmaceutical Technology Co. Ltd. A from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.46 Billion | +13.39% |
| 2023-12-31 | CN¥1.29 Billion | -26.71% |
| 2022-12-31 | CN¥1.76 Billion | +133.54% |
| 2021-12-31 | CN¥754.27 Million | -- |